{
  "id": "641461bb201352f04a000046",
  "type": "summary",
  "question": "What is a PROTAC?",
  "ideal_answer": "A PROTAC is a heterobifunctional molecule that induces protein degradation by forming a ternary complex between a target protein and an E3 ubiquitin ligase. It consists of two ligands - one that binds to the target protein and the other that recruits the E3 ubiquitin ligase",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32082969",
    "http://www.ncbi.nlm.nih.gov/pubmed/28379698",
    "http://www.ncbi.nlm.nih.gov/pubmed/31064868",
    "http://www.ncbi.nlm.nih.gov/pubmed/33406191",
    "http://www.ncbi.nlm.nih.gov/pubmed/36139095",
    "http://www.ncbi.nlm.nih.gov/pubmed/25305486",
    "http://www.ncbi.nlm.nih.gov/pubmed/35410300",
    "http://www.ncbi.nlm.nih.gov/pubmed/30427680",
    "http://www.ncbi.nlm.nih.gov/pubmed/35671157",
    "http://www.ncbi.nlm.nih.gov/pubmed/35311871",
    "http://www.ncbi.nlm.nih.gov/pubmed/30672516",
    "http://www.ncbi.nlm.nih.gov/pubmed/33010159",
    "http://www.ncbi.nlm.nih.gov/pubmed/16338398",
    "http://www.ncbi.nlm.nih.gov/pubmed/34240523",
    "http://www.ncbi.nlm.nih.gov/pubmed/33160761",
    "http://www.ncbi.nlm.nih.gov/pubmed/31708096",
    "http://www.ncbi.nlm.nih.gov/pubmed/33860212",
    "http://www.ncbi.nlm.nih.gov/pubmed/35500825",
    "http://www.ncbi.nlm.nih.gov/pubmed/35412837",
    "http://www.ncbi.nlm.nih.gov/pubmed/34560429",
    "http://www.ncbi.nlm.nih.gov/pubmed/35948047",
    "http://www.ncbi.nlm.nih.gov/pubmed/36321238",
    "http://www.ncbi.nlm.nih.gov/pubmed/34100597",
    "http://www.ncbi.nlm.nih.gov/pubmed/35242765",
    "http://www.ncbi.nlm.nih.gov/pubmed/33081540",
    "http://www.ncbi.nlm.nih.gov/pubmed/34081921",
    "http://www.ncbi.nlm.nih.gov/pubmed/31004963",
    "http://www.ncbi.nlm.nih.gov/pubmed/35680848",
    "http://www.ncbi.nlm.nih.gov/pubmed/32404196",
    "http://www.ncbi.nlm.nih.gov/pubmed/36300631",
    "http://www.ncbi.nlm.nih.gov/pubmed/18752944"
  ],
  "snippets": [
    {
      "text": "PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-degradation strategy that has emerged in recent years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35680848",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of one ligand that binds to a protein of interest (POI) and another that can recruit an E3 ubiquitin ligase. The chemically-induced proximity between the POI and E3 ligase results in ubiquitination and subsequent degradation of the POI by the ubiquitin-proteasome system (UPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671157",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis targeting chimeras (PROTACs) are molecules that induce protein degradation via formation of ternary complexes between an E3 ubiquitin ligase and a target protein. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412837",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (PROTAC) results in a compound that induces degradation of FLT-3 ITD mutant at low nanomolar concentrations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30427680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent degradation of protein of interest.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31064868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PROteolysis-TArgeting Chimera (PROTAC) is an innovative strategy that takes advantage by the cell's own Ubiquitin-Proteasome System (UPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35242765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we describe the design of a novel PROTAC (proteolysis targeting chimeric molecule) capable of simultaneously inducing the degradation of the X-protein, and antagonizing its function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25305486",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18752944",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs) are small molecules that specifically link E3 ubiquitin ligases to proteins of interest to mediate targeted ubiquitination and degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35500825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have previously reported a library of proteolysis targeting chimeras (PROTACs) incorporating a benzamide-based HDAC ligand (from CI-994), with an alkyl linker and ligand for the von Hippel-Lindau (VHL) E3 ubiquitin ligase that degrade HDAC1-3 at submicromolar concentrations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35948047",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35410300",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PROTACs are the heterobifunctional nano molecules with size range of about 10 nanometres find application to eliminate the protein complexes formed by protein-protein interaction through large and flat surface generally defined as \"undruggable\" in conventional drug delivery system, which include around 85 % of proteins present in humans, suggesting their wide application in the field of drug development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36321238",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: PROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33081540",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A technology was developed known as Protac (Proteolysis Targeting Chimeric Molecule) that acts as a bridge, bringing together the SCF ubiquitin ligase with a protein target, resulting in its ubiquitination and degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16338398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "uary 2013 through June 2020. Only English-language patent applications with exemplified PROTACs reported to degrade a target protein(s) were deemed in scope, and the definition of 'PROTAC' was restricted to a bifunctional molecule which contains a discrete binding element for a specific degradation target(s), as well as a separate discrete E3 ligase-binding moiety.EXPERT OPINION: Delivering on the enormous potential of PROTACs will require the development of PROTAC medicines that are differentiate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33081540",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis targeting chimeras (PROTACs) are hetero-bifunctional molecules that could simultaneously bind to the target protein and the E3 ubiquitin ligase, thereby leading to selective degradation of the target protein.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PROTACs (proteolysis targeting chimeras) emerge as a powerful class of therapeutic modalities, which rely on induced protein-protein interactions between the proteins of interest (POIs) and E3 ubiquitin ligases to aid the degradation of POIs by the ubiquitin-proteasome system (UPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34100597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degradation of CRBN.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis Targeting Chimeras (PROTACs) are a new promising class of small molecules that can effectively direct specific proteins to proteasomal degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34560429",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ability to selectively degrade target proteins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32082969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteaso",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33160761",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300631",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel ther",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule c",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in re",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36139095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300631",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of interest (POI) induces its ubiquitination-based proteolysis by recruiting an E3 ligase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34081921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in recent years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36139095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug discovery paradigm which has been widely used as biological tools and medicinal molecules with the potential of clinical application value.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33160761",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs) degrade target proteins by engaging the ubiquitin-proteasome system. Assays detecting target-PROTAC-E3 ligase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33860212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28379698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A parallel, one-pot assembly approach to proteolysis targeting chimeras (PROTACs) is demonstrated utilizing activated esters generated in situ, and traceless Staudinger ligation chemistry.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406191",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Development of proteolysis targeting chimeras (PROTACs) is emerging as a promising strategy for targeted protein degradation. However, the drug develo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34240523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3). Upon binding to the POI, the PROTAC can recruit E3 for POI ubiquitination, which is subjected to proteasome-mediated degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Targeted protein degradation using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery. PROTACs mediate the degradation of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degradation by the 26S proteasome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31004963",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35410300",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}